| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.4 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |